Acumen Pharmaceuticals Announces Positive Topline Results for Alzheimer’s Disease Treatment
Acumen Pharmaceuticals, Inc., (Nasdaq: ABOS) has reported positive topline results from its first in human Phase 1 study of ACU193 as a treatment for early Alzheimer’s disease (AD). ACU193 is the first clinical-stage AβO targeting antibody therapy in early AD.
Acumen’s share price soared more than 60% following the news.
The company’s INTERCEPT-AD clinical trial is a US-based Phase 1, multi-center, randomized, double-blind, placebo-controlled study evaluating the safety and tolerability, and establishing clinical proof of mechanism, of ACU193 in patients with early AD.
Sixty-five individuals with early AD enrolled in this first-in-human study of ACU193.
The trial is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and target engagement of intravenous doses of ACU193.
ACU193 has been granted Fast Track designation for the treatment of early Alzheimer’s disease by the U.S. Food and Drug Administration.
About Acumen Pharmaceuticals
Acumen, headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble AβOs. For more information, visit www.acumenpharm.com.